Comparison of dose distributions hippocampus in high grade gliomas irradiation with linac-based IMRT and volumetric arc therapy: a dosimetric study

Emine Canyilmaz1*, Gonca Dilek Hanedan Uslu2, Fatma Colak1, Burcin Hazeralı3, Emel Haciislamoglu1, Ahmet Yasar Zengin2, Ahmet Sari1 and Adnan Yoney1

Abstract
The aim of this study was to assess the feasibility of sparing contralateral hippocampus during partial brain radiotherapy in high grade gliomas. 20 previously treated patients were replanned to 60 Gy in 30 fractions with sparing intensity-modulated radiotherapy (IMRT) and volumetric modulated arctherapy (VMAT) using the following planning objectives: 100 % of PTV covered by 95% isodose without violating organs at risk (OAR) and hot spot dose constraints. For each, standard intensity-modulated radiotherapy (IMRT) plans were generated, as well as sparing IMRT and VMAT plans which spared contralateral (hemispheric cases) hippocampus. When the three plans were compared, there was equivalent PTV coverage, homogeneity, and conformality. Sparing IMRT significantly reduced maximum, mean, V20, V30 and V40 hippocampus doses compared with standard IMRT and VMAT (p < 0.05). VMAT significantly reduced maximum left lens and mean eye doses compared with standard IMRT and sparing IMRT (p < 0.05). Brainstem, chiasm, left and right optic nerves, right eyes and lens doses were similar. VMAT significantly reduced monitor units compared with standard IMRT and sparing IMRT (p < 0.05). It is possible to spare contralateral hippocampus during PBRT for high grade gliomas using IMRT. This approach may reduce late cognitive sequelae of cranial radiotherapy.

Keywords: Glioma; Hippocampus; IMRT; Partial brain radiotherapy; VMAT

Introduction
The prognosis of the patients with high grade gliomas had improved with the combination of radiotherapy and chemotherapy. While expected life time has improved, the ratio of late side effects of radiotherapy has also increased (Stupp et al. 2009). Side effects are more frequent in children after partial brain radiotherapy (PBR). These side effects include cognitive dysfunctions, endocrine dysfunctions, visual loss, hearing loss, myelopathy, vasculopathies and the induction of secondary tumours including gliomas (high and low grade), sarcomas and meningiomas (Merchant et al. 2005; Nandagopal et al. 2008; Kondoh et al. 2003; Douw et al. 2009; Crossen et al. 1994; Kortmann et al. 2003) Clear dose–volume relationships exist for many of these late adverse events. However, no clear dose–response relationships have been proven for cognitive dysfunction and secondary tumour induction (Merchant et al. 2005; Marks et al. 1981). These side effects are seen less often in elderly patients (Douw et al. 2009). Nevertheless, without necrosis, radiation induced cognitive dysfunction and leuko-encephalopathy are the most often complications in patients with long-term survival (Crossen et al. 1994). This clinical presentation is different than radiation necrosis in terms of clinic-radiology and pathology. The most clinically dramatic side effect is radiation induced dementia, and it is characterized by memory loss, attention deficit and emotional changes (Armstrong et al. 1995; Vigliani et al. 1997). Frequent memory loss and other cognitive deficits are induced by radiotherapy in the hippocampus and limbic system. According to clinical

* Correspondence: dremocan@ktu.edu.tr
1Department of Radiation Oncology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey
Full list of author information is available at the end of the article

© 2015 Canyilmaz et al; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
and pre-clinical study results, the key role of neurocognitive deficit pathogenesis induced by cranial radiotherapy takes place in the neural stem cell compartment of the hippocampus (Raber et al. 2004; Nagai et al. 2000; Peissner et al. 1999; Roman and Sperduto 1995). The hippocampus is a paired brain structure, located in the ventromedial part of the temporal lobes, laying lateral to the temporal horn of the lateral ventricle. Bilateral and unilateral radiation injury of the hippocampus is known to alter learning and memory formation (Tofilon and Fike 2000). Clinical data defining a clear dose–response effect does not exist but there is a suggestion that more than 30 Gy to the temporal lobe may be relevant (Armstrong et al. 2010).

Intensity modulated radiotherapy (IMRT) can allow dosage increase in high grade gliomas as well as reduce late toxicity due to radiotherapy. According to a retrospective analysis that compared IMRT with conformal radiation therapy, IMRT provided equal overall survival without prognosis change, and it decreases acute and late neurotoxicity (Merchant et al. 2005). In dosimetric studies of high grade gliomas, when IMRT is compared with three-dimensional conformal irradiation, IMRT is superior in limiting exposure for organs at risk (OAR) and allows for the planned target volume coverage (Narayana et al. 2006; MacDonald et al. 2007). As an extension of IMRT, volumetric modulated arc therapy (VMAT) is currently in use for the treatment of many cancers. Gantry arc-based IMRT delivery methods involve the gantry rotating around the patient while the multileaf collimator (MLC) leaf positions, dose rate and gantry speed are varied simultaneously (Otto 2008).

This current dosimetric study was conducted to evaluate the preservability of the contralateral hippocampus, in case of ipsilateral hippocampus invasion by a tumor during PBRT in high grade hemispheric gliomas.

**Methods and materials**

We identified 20 patients with high-grade glioma who previously have been treated in our department with PBRT. Patient and tumor characteristics are shown in Table 1. In our study, we used CT scans of 20 patients diagnosed with hemispheric high grade glioma in our clinic after approval of ethical committee. Patients were immobilized in the supine position using an individualized thermoplastic mask. CT and magnetic resonance imaging scans were performed, both with a 2.5-mm slice thickness, and were used to aid tumor delineation. We reloaded CT scans that were used in the treatment of the patients and archived in CT-simulator into the Eclipse treatment planning system. Target volume and OAR identified in the CT scans of all patients were contoured by a radiation oncologist to prevent personal contouring differences that could skew the study results. Two researchers, one of which is a radiologist, evaluated the contouring. We made IMRT planning suitable to dosage constraints in our study using Eclipse TPS in our department. Afterwards, CT scans were transferred to another treatment center to make VMAT planning.

For each patient, two intensity-modulated radiotherapy treatment plans and VMAT plans were generated using the eclipse Version 10.1 treatment planning system. All IMRT and VMAT plans were generated using 6-mv for a linear accelerator and 120-leaf multileaf collimator (MLC) (5-mm width leaves over target extent). For both techniques, final dose calculations were performed using the single pencil beam algorithm in Eclipse. The DVH calculations were also performed in Eclipse.

The standard IMRT plan, designated standard, did not include hippocampus as avoidance structures in optimisation criteria. The sparing IMRT and VMAT plans, designated sparing, did introduce hippocampus as avoidance structures. Optic nerve, chiasma, brain stem, eyes and lenses were the structures contoured in the study as OAR. The hippocampus was contoured on T1-weighted MRI axial sequences. The contralateral hippocampus was contoured by the reference of Gondi et al (Gondi et al. 2010). The baseline optimisation criteria for the high grade glioma cases are shown in Table 2.

In the traditional IMRT and VMAT plans, the prescription dose for phase I was 46Gy in 23 fractions delivered to PTV 46Gy, followed by a sequential cone down boost of 14Gy in seven fractions delivered to PTV 60Gy. For all

| Total number of patients | 20 |
|--------------------------|----|
| Age                      | Median 53 years |
|                         | Range 31–75 years |
| Sex                      | Male 13 |
|                         | Female 7 |
| CTV size                 | <6 cm 6 |
|                         | >6 cm 14 |
| Location                 | Frontal 2 |
|                         | Parietal 5 |
|                         | Temporal 5 |
|                         | Temporo-parietal 3 |
|                         | Fronto-temporal 2 |
|                         | Temporo-okcipital 3 |
| Contralateral hippocampal volume cm³ | Median 2.6 |
|                         | Range 1.9-3.4 |
plans, the following structures were contoured: gross tumor volume (GTV) (gross enhancing tumour and resection cavity as identified on postoperative MRI T1 post-contrast sequences), peri- tumoural oedema (as identified on postoperative MRI T2 fluid attenuated inversion recovery sequences), clinical treatment volume (CTV) 46Gy (GTV + peri-tumoural oedema + 2-cm anatomically constrained margins), PTV46Gy (CTV 46Gy + 5-mm margin), CTV 60Gy in IMRT plans (GTV + anatomically constrained 2-cm margin), PTV 60Gy in IMRT plans (CTV60Gy + 5-mm margin) (Chang et al. 2007; Nelson et al. 1993). Two different IMRT plans were performed for standard and sparing IMRT. The first IMRT plan set used seven beams (0°, 51°, 102°, 153°, 204°, 255°, 306°) isocentrically centered on the PTV for PTV 46. The second IMRT plan set used five beams isocentrically centered on the PTV for PTV 60. Five field IMRT plan special to each patient with angles according to the tumor location. All beams were collimated to minimize exposure to the hippocampus. The dose homogeneity goal was < 110% within the PTV. Achieve at least 100% coverage of PTV with the 95% isodose of 46 and 60 Gy without violating OAR maximum dose constraints.

The VMAT plans were generated using an in-house inverse planning approach, in which MLC-shaped fields were progressively added throughout a single 360 arc during optimization. The dose rate was between 0 and 600MU/min and gantry rotation between 0.0°/s and a maximum of 4.8°/s. The collimator was rotated to about 45° to 315° to minimize the contribution of the tongue-and Groove effect during treatment. The MLC constraints are included in the optimization, ensuring that the plan is always deliverable. Inhomogeneity corrections were not implemented for this in-house planning system and were therefore not used during optimization or final dose calculation. In VMAT planning, we used 2 arc plan to decide the most suitable treatment plan for PTV46 and PTV60. After failing to obtain dose homogeneity for PTV, we made 1 arc and 3 arc VMAT plans. As a result, we decided to use 2 arc VMAT planning because of highest PTV homogeneity. Both for PTV 46 and PTV 60; we used 45° collimation between 182°-178°, 178°-182° angles for the planning of patients with right hemispheric localization. We used 45°collimation between 178°-182° and 182°-178°, for planning of patients with left hemispheric localization.

**Evaluation of treatment plans**

A comparative analysis was then performed using the twenty computed tomography data sets. Dosimetric parameters were evaluated for target volumes and OARs. For PTV, the comparison parameters included maximum dose (D_max), mean dose (D_mean), D95%, conformity index (CI), and homogeneity index (HI). We evaluated D_mean and D_max for the hippocampus, Dmax dose for lens, eyes, optic nerves, brain stem, and chiasm for OARs.

The CI of the PTV was defined as:

\[
CI = \frac{V_{PTV} \times V_{TV}}{\text{TV}^2}
\]

\[
V_{PTV} \text{ Volume of PTV, } V_{TV} \text{ Volume of TV inside of treatment volume for identified isodose.}
\]

The HI of the PTV was defined by using this formula:

\[
HI = \frac{D5%}{D95%}
\]

D5%; Dose received by 5% of PTV, D95% Dose received by 95% of PTV (Ding et al. 2006; Lee et al. 2012).

**Statistical analysis**

Dose-volume histograms (DVH) were used in the comparison of the target volume and at-risk organ doses in all the treatment plans. In the comparison of the data, if parametric conditions were provided, ANOVA post hoc was used, otherwise, the Kruskal-Wallis Test was used. In the paired group comparisons of quantifiable data, if parametric conditions were provided the Bonferroni Modified test was applied, otherwise the Mann-Whitney U-test was used. All statistical tests were two-sided, with a threshold

| Structure       | Optimisation criteria                          |
|-----------------|-----------------------------------------------|
| **Initial phase (46 Gy in 23 fractions to PTV 46 Gy)** | |
| PTV 46 Gy       | 95% to receive 46 Gy                          |
| Right eye       | 0% to receive 30 Gy                           |
| Left eye        | 0% to receive 30 Gy                           |
| Right lens      | 0% to receive 6 Gy                            |
| Left lens       | 0% to receive 6 Gy                            |
| Right optic nerve | 0% to receive 42 Gy                         |
| Left optic nerve | 0% to receive 42 Gy                         |
| Optic chiasm    | 0% to receive 42 Gy                           |
| Brainstem       | 0% to receive 42 Gy                           |
| Hippocampus     | 0% to receive 15 Gy                           |
| **Boost phase (14 Gy in seven fractions to PTV 60 Gy)** | |
| PTV 60 Gy       | 95% to receive 14 Gy                          |
| Right eye       | 0% to receive 5 Gy                            |
| Left eye        | 0% to receive 5 Gy                            |
| Right lens      | 0% to receive 4 Gy                            |
| Left lens       | 0% to receive 4 Gy                            |
| Right optic nerve | 0% to receive 12 Gy                         |
| Left optic nerve | 0% to receive 12 Gy                         |
| Optic chiasm    | 0% to receive 12 Gy                           |
| Brainstem       | 0% to receive 12 Gy                           |
| Hippocampus     | 0% to receive 5 Gy                            |

**Table 2 Baseline optimization criteria for all plans**
for statistical significance of P < 0.05. Statistical analysis was carried out utilizing SPSS version 13.

Results
Coverage of the treatment target (PTV60 Gy and PTV46 Gy in the high-grade glioma plans) were essentially identical in the Standard IMRT, Sparing IMRT, and VMAT plans, with the whole target receiving at least 95% of the prescription dose (D100 95%). All IMRT and VMAT plans were able to meet the constraints placed on the OAR, as well as PTV. All plans were optimised to keep the maximum dose within the target to <110% of the prescription dose (Dmax < 110%), and all plans were able to meet this objective. The PTV coverage, conformality, and homogeneity were equivalent with VMAT and IMRT. Comparing VMAT with all IMRT, maximum doses to the brainstem, chiasm, left and right optic nerves, right eyes and lens doses were similar. VMAT significantly reduced maximum left eye and lens doses compared with standard IMRT and sparing IMRT (p < 0.05). There was a statistically significant difference noted between the three plans in terms of monitor units (p < 0.05). The mean MU to treat a 2-Gy fraction was 1472 (1041-1834) with standard IMRT, compared with 1320 (1116-1993) sparing IMRT and with 994 (886-1150) VMAT. Lowest mean monitor unit value was received in VMAT planning despite two arc. These dosimetric outcomes are shown in Table 3.

The lowest mean and max doses for the hippocampus were found in the sparing IMRT planning, and this result was statistically significant (p < 0.05). In V10, V20, V30, and V40 dose values for the hippocampus in standard IMRT planning, we observed a larger decrease in sparing planning comparing to VMAT planning (Table 4), (Figure 1).

Discussion
Cognitive and endocrine dysfunctions are both important and recognized problems after PBRT and complete brain radiotherapy in pediatric as well as mature patients (Merchant et al. 2005; Nandagopal et al. 2008; Kondoh et al. 2003; Douw et al. 2009). Standard treatment includes maximal safe surgical debulking and adjuvant radiotherapy, with chemotherapy for high grade glioma. Better results of glioma therapies with treatments in recent years make these side effects more visible (Stupp et al. 2009). For this reason, we should focus efforts to protect the cognitive function in this cohort of patients.

This study aims to show preservation of the hippocampus in high grade glioma patients during different planning techniques. In our study, we did not aim to preserve the hippocampus in the same hemisphere with the tumor, because in many cases the ipsilateral hippocampus is affected by the tumor directly or by tumor edema indirectly. Relapse risk is increased if the ipsilateral hippocampus is protected in high grade gliomas (Chan et al. 2002). As is known, relapses occur most often within two cm diameter of tumor origin in high grade gliomas. This is one of the main reasons for treatment failure as is shown in many reports (Marsh et al. 2011). In addition, the hippocampus, the limbic system, and neural stem cell compartments are structures that are present bilaterally in human body.

| Table 3 Dosimetric comparison of Standard IMRT plan, Sparing IMRT plan and VMAT plan for PTV 46 and 60 plans |
|----------------------------------------------------------------------------------------------------------------|
| **PTV46 max dose (Gy)** | 46.9 (46.2-47.4) | 47 (46.5-47.6) | 47.5 (48.5-50.1) | 0.14 |
| **PTV46 mean dose (Gy)** | 48.9 (48.5-49.4) | 49.3 (48.3-50.8) | 48.5 (47.9-50.4) | 0.21 |
| **D 95 46 (Gy) mean SD** | 46 (45.7-46.3) | 46 (45.8-46.3) | 46.4 (45.8-46.8) | 0.55 |
| **PTV60 max dose (Gy)** | 63.2 (60.7-62.2) | 63.4 (60.7-62.1) | 63.6 (61.2-62.6) | 0.44 |
| **PTV60 mean dose (Gy)** | 61 (61-64.3) | 61.2 (62.4-64.9) | 61.4 (61.3-64.6) | 0.23 |
| **D 95 60 (Gy)** | 60 (59.9-60.2) | 60 (59.9-60.3) | 60 (59.9-61.5) | 0.65 |
| **HI (60 Gy)** | 1.03 (1.02-1.05) | 1.03 (1.02-1.04) | 1.03 (1.02-1.04) | 0.34 |
| **CI (60 Gy)** | 1.2 (1-1.4) | 1.2 (1.1-1.6) | 1.2 (0.9-1.6) | 0.48 |
| **MU (0-60 Gy)** | 1472 (1041-1834) | 1320 (1116-1993) | 994 (886-1150) | 0.01 |
| **Right lens max** | 4.8 (2.5-9.3) | 5.2 (2.8-9.3) | 7.5 (4.1-10.8) | 0.1 |
| **Left lens max** | 7.7 (4.6-10.3) | 6.1 (3.8-9.8) | 4.0 (3.7-9.9) | 0.001 |
| **Right eye mean** | 8.3 (4.2-15.8) | 9.4 (5.1-16.7) | 10.3 (3.6-17.6) | 0.45 |
| **Left eye mean** | 10.8 (4.2-19.7) | 9.4 (6.2-16.2) | 8.4 (5.9-16.3) | 0.023 |
| **Right optic nerve max** | 35.1 (29.2-41.0) | 35.7 (30.6-40.8) | 32.2 (25.3-39.1) | 0.65 |
| **Left optic nerve max** | 36.1 (30.2-42.1) | 37.9 (32.4-43.5) | 33.2 (25.6-40.8) | 0.55 |
| **Optic chiasm max** | 39.8 (33.7-45.6) | 43.2 (37.9-48.5) | 37 (29.6-45.2) | 0.7 |
| **Brainstem max** | 51.1 (48.2-54.3) | 50.9 (48.3-54.5) | 50.1 (48.9-54.1) | 0.44 |
Memory loss or other cognitive dysfunctions are not monitored in patients who have undergone temporal lobectomy due to persistent epilepsy (Di Gennaro et al. 2006; Giovagnoli et al. 2007). This gives rise to thought of one normal medial temporal lobe is enough for normal memory function. Therefore in this dosimetric study, we aimed to protect the contralateral hippocampus during PBRT.

The clinical tolerance of the hippocampus to radiation is not well described but likely to vary according to patient age, total dose, dose per fraction, time between fractions, and the distribution of dose within it. Functional representation in the hippocampus of the dominant and non-dominant hemispheres may not be interchangeable and therefore the optimal dose constraint may change and not simply depend on the laterality of the tumour. Johannesen et al. (Johannesen et al. 2003) researched changes in white matter using MRI scans of patients who received median 54 Gy cranial radiotherapy. According to the results of the mentioned study, there were changes noted in the white matter in T2 and FLAIR sequences of MRI above 29.2 Gy doses, however there was no change between 12.5-27.5 Gy. Also, researchers noted a relationship between grade 3 white matter changes in MRI T2 and FLAIR sequences with a lower quality of life as well as increase in side effects. In a pediatric study, Armstrong et al. (Armstrong et al. 2010) identified a relationship between memory loss and exposure of temporal lobe over 30 Gy. In a study conducted in mature adults, it is reported that 40 Gy or more exposure of brain leads to a change in the metabolic activity of the brain and effects neuro-cognitive functions (Hahn et al. 2009).

In a dosimetric study that comparing treatment plans in high grade gliomas while preventing contralateral hippocampus exposure, mean value for hippocampus in standard IMRT planning was 36.6 and it was found to be 15.8 Gy in sparing IMRT planning (Marsh et al. 2011). Another dosimetric study in the same group of patients reported a hippocampus mean value of 35.1 Gy, max dose 46.6 Gy in standard IMRT planning, and a mean dose 19.7 Gy, max dose 33.1 Gy in sparing IMRT planning (Marsh et al. 2013). In another study consisting of eighteen patients with grade II and III glioma, the contralateral hippocampus mean dose was reported as 24.9 Gy. Despite no clinical data identifying optimal hippocampus mean dose, a dose between 15.8 and 24.9 Gy is generally considered for protecting neuro-cognitive functions (Pinkham et al. 2013). In our study, only sparing IMRT plan reached the determined mean and max dose values for the contralateral hippocampus. In standart

| Table 4 Comparison of hippocampus between mean,max,V10, V20, V30, and V40 doses |
|----------------------------------|------------------|----------|---------|-----------------|
|                                  | Standard IMRT Plan | Sparing IMRT Plan | VMAT plan | p value |
| Hippocampus Mean dose (Gy)       | 32.4             | 15.07    | 17.2    | 0.001          |
| Hippocampus Max Dose (Gy)        | 44.8             | 39.9     | 27.7    | 0.001          |
| Hippocampus V10 mean dose (Gy)   | 100              | 80.4     | 92.4    | 0.002          |
| Hippocampus V20 mean Dose (Gy)   | 98.9             | 17.3     | 38.7    | 0.001          |
| Hippocampus V30 mean dose (Gy)   | 71.7             | 4.1      | 0       | 0.001          |
| Hippocampus V40 mean (Dose Gy)   | 5                | 0.7      | 0       | 0.002          |

Figure 1 Dose distributions and dose volume histograms.
IMRT plan contralateral hippocampus mean dose was 32.4 Gy and max dose was 44.8 Gy, while in VMAT plan mean dose was 17.2 Gy and max dose was 27.7 and in sparing IMRT plan mean dose was 15 Gy and max dose was 39.9 Gy. When the literature is examined, hippocampus mean dose values found in our study were lower compared to other studies.

In a dosimetric study comparing IMRT and VMAT planning in high grade gliomas, at OARs doses in IMRT planning were similar to our study however were higher for VMAT planning. In the same study, a reduction ratio of doses received by risky organs in VMAT planning was found statistically significant comparing to IMRT planning (Shafer et al. 2010). In our study we were unable to show a statistically significant difference in doses received by at OARs in all three plans. However, contralateral hippocampus V10, V20, V30 and V40 dose values of the contralateral hippocampus of standard IMRT planning provided more reduction in sparing IMRT planning comparing to VMAT planning. We chose two arc plans instead of one arc in our study. In the two arc VMAT treatment plan, at OARs including the hippocampus were exposed to more dosage in comparison to other studies.

There was no statistically significant difference determined in regards to HI, CI, and PTV coverage. This data is similar to reports by Shafer et al. (Shafer et al. 2010). In the present study, monitor unit values of both IMRT planning and VMAT planning were found higher. In that study, seven fields for single PTV 60 in IMRT planning and single arc for single PTV 60 in VMAT planning were conducted (Shafer et al. 2010). However in our study seven fields with standard angles for PTV 46 in IMRT planning and five fields identified according to tumor localization for PTV 60 were conducted. This explains higher mean monitor unit values in our study.

Conclusion

This study aimed to show preservability of the hippocampus in different treatment techniques for patients who receive partial brain radiotherapy for high grade gliomas. While deciding for treatment plan of patients, the dose received by at OAR should be considered as treatment plan homogeneity. The lowest dose value for the hippocampus was identified in sparing IMRT planning for this study. This treatment plan can lower neuro-cognitive dysfunction, a late side effect of cranial radiotherapy. However, this should be supported with further studies that show the relationship between dose received by hippocampus during PBRT in high grade gliomas and neuro-cognitive dysfunctions.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

EC carried out the study concept, design, literature search and manuscript writing. GHU carried out the study design, literature search and manuscript preparation. FC carried out the IMRT plans and data acquisition manuscript preparation. BH carried out the VMAT plans and data acquisition manuscript preparation. EH checked treatment plans for study, AYZ carried out the literature search. AS has made the radiological control for study. AY carried out the manuscript editing and manuscript review. All authors read and approved the final manuscript.

Author details

1Department of Radiation Oncology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey. 2Department of Radiation Oncology, Kanuni Research and Education Hospital, Trabzon, Turkey. 3Onkomer Oncology Center, Izmir, Turkey.

Received: 18 December 2014 Accepted: 18 February 2015

Published online: 05 March 2015

References

Armstrong C, Ruffer J, Corn B, DeVries K, Rollman J (1995) Biphasic patterns of memory deficits following moderate-dose partial-brain irradiation: neuropsychologic outcome and proposed mechanisms. J Clin Oncol 13:2263–71

Armstrong GT, Jain N, Liu W, Merchant TE, Stovall M, Sivastava DK, Gurney JG, Packer RJ, Robson LL, Knull RR (2010) Regional-specific radiotherapy and neuropsychological outcomes in adult survivors of childhood CNS malignancies. Neuro Oncol 12:1173–86

Chan JL, Lee SW, Faass BA, Normolle DP, Greenberg HS, Junck LR, Egbarski SS, Sandler HM (2002) Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 20:1635–42

Chang EL, Akyurek S, Avalos T, Rebuerno N, Spencer C, Garcia J, Farnigletti R, Allen PK, Chao KS, Mahajan A, Woo SY, Maor MH (2007) Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma. Int J Radiat Oncol Biol Phys 68:144–150

Crossen JR, Garwood D, Glatstein E, Neuvelt EA (1994) Neuropathologic sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol 12:2677–42

Di Gennaro G, Grammado LG, Quarto PA, Esposito V, Mascia A, Sparano A, Meldelesi GN, Picardi A (2006) Severe amnesia following bilateralanterior temporal lobe damage occurring on two distinct tocasions. Neurol Sci 27:129–33

Ding M, Newman F, Kavanagh BD, Stuhlk J, Johnson TK, Gaspar LE (2006) Comparative dosimetric study of three-dimensional conformal, dynamic conformal arc, and intensity-modulated radiotherapy for brain tumor treatment using Novatis system. Int J Radiat Oncol Biol Phys 66:82–96

Drouet L, Klein M, Fagel SS, van den Heuvel J, Taphoorn MJ, Aaronson NK, Postma TJ, Vandempop WP, Moleij J, Boerman RH, Beute GN, Slumiter JD, Slotman BI, Reijneveld JC, Heimans JJ (2009) Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol 8:110–18

Giovagnoli AR, Casaza M, Ciceri E, Avanzini G, Broggi G (2007) Preserved memory in temporal lobe epilepsy patients after surgery for low-grade tumour. A pilot study. Neurol Sci 28:251–8

Gondi V, Tolakanahalli R, Mehta MP, Tewatia D, Rowley H, Kuo JS, Khuntia D, Tomé WA (2010) Hippocampal-sparing whole-brain radiotherapy: a “how-to” technique using helical tomotherapy and linear accelerator-based intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 78:1244–52

Hahn CA, Zhou SM, Raynor R, Tisch A, Shafman T, Wong T, Kirkpatrick J, Armstrong GT, Jain N, Liu W, Merchant TE, Stovall M, Sivastava DK, Gurney JG, Packer RJ, Robson LL, Knull RR (2009) Dose-dependent effects of radiotherapy on cerebral blood flow, metabolism, and neurocognitive dysfunction. Int J Radiat Oncol Biol Phys 73:1082–7

Johannesen TB, Lien HH, Hole KH, Lote K (2003) Radiological and clinical assessment of long-term brain tumour survivors after radiotherapy. Radiother Oncol 69:169–76

Kondoh T, Morishita A, Kamei M, Okamura Y, Tamaki M, Kohmura E (2003) Moyamoya syndrome after prophylactic cranial irradiation for acute lymphocytic leukemia. Pediatr Neurosurg 39:264–69

Kortmann RD, Timmermann B, Taylor RE, Scarchelli G, Plasswilm L, Paulsen F, Jeremic B, Gnekow AK, Diekmann B, Kay S, Barnberg M (2003) Current and future strategies in radiotherapy of childhood low-grade glioma of the brain. Part II: treatment-related late toxicity. strahlenther Onkol 179:585–97
Lee TF, Ting HM, Chao PJ, Fang FM (2012) Dual arc volumetric-modulated arc radiotherapy (VMAT) of nasopharyngeal carcinomas: a simultaneous integrated boost treatment plan comparison with intensity-modulated radiotherapies and single arc VMAT. Clin Oncol (R Coll Radiol) 24:196–207

MacDonald SM, Ahmad S, Kachris S, Vogds BJ, DeBruin M, Gittleman AE, De Wijngaert K, Vlachaki MT (2007) Intensity modulated radiation therapy versus three-dimensional conformal radiation therapy for the treatment of high grade glioma: a dosimetric comparison. J Appl Clin Med Phys 8(2):47–60

Marks JE, Baglan RJ, Prassad SC, Blank WF (1981) Cerebral radionecrosis: incidence and risk in relation to dose, time, fractionation, and volume. Int J Radiat Oncol Biol Phys 7:493–52

Marsh JC, Godbole R, Diaz AZ, Gelda BT, Turian JV (2011) Sparing of the hippocampus, limbic circuit and neural stem cell compartment during partial brain radiotherapy for glioma: a dosimetric feasibility study. J Med Imaging Radiat Oncol 55:442–449

Marsh CJ, Ziel GE, Diaz AZ, Wendt JA, Godbole R, Turian JV (2013) Integral dose delivered to normal brain with conventional intensity-modulated radiotherapy (IMRT) and helical tomotherapy IMRT during partial brain radiotherapy for high-grade gliomas with and without selective sparing of the hippocampus, limbic circuit and neural stem cell compartment. J Med Imaging Radiat Oncol 57:378–383

Merchant TE, Kiehna EN, Li C, Xiong X, Mulhem RK (2005) Radiation dosimetry predicts IQ after conformal radiation therapy in pediatric patients with localized ependymoma. Int J Radiat Oncol Biol Phys 63:1546–54

Nagai R, Tsunoda S, Hori Y, Asada H (2000) Selective vulnerability to radiation in the hippocampal dentate granule cells. Surg Neurol 53:503–6

Nandagopal R, Lavendière C, Mullooney D, Hudson MM, Meacham L (2008) Endocrine late effects of childhood cancer therapy: a report from the Children’s Oncology Group. Horm Res 69:65–74

Narayana A, Yamada J, Berry S, Shah P, Hunt M, Gutin PH, Leibel SA (2006) Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results. Int J Radiat Oncol Biol Phys 64:892–897

Nelson DJ, Curran WJ Jr, Scott C, Nelson JS, Weinstein AS, Ahmad K, Constine LS, Murray K, Powlis WD, Moliuddin M (1993) Fischbach J. Hyperfractionated radiation therapy and bis-chlorethyl nitrosourea in the treatment of malignant gliomas—possible advantage observed at 72.0 Gy in 1.2 Gy B.I.D. fractions: report of the Radiation Therapy Oncology Group Protocol 8302. Int J Radiat Oncol Biol Phys 25:193–207

Otto K (2008) Volumetric modulated arc therapy IMRT in a single gantry arc. Med Phys 35:310–17

Peirson W, Kocher M, Treuer H, Gillardon F (1999) Ionizing radiation-induced apoptosis of proliferating stem cells in the dentate gyrus of the adult rat hippocampus. Brain Res Mol Brain Res 71:61–8

Pinkham MB, Bertrand KC, Olson S, Zarate D, Oram J, Pullar A, Foote MC (2013) Foote Hippocampal-sparing radiotherapy: The new standard of care for World Health Organization grade II and III gliomas? J Clin Neurosci 30:967–5868

Raber J, Rola R, LeFevour A, Morhardt D, Curley J, Mizumatsu S, VandenBerg SR, Fike JR (2004) Radiation-induced cognitive impairments are associated with changes in indicators of hippocampal neurogenesis. Radiat Res 162:39–47

Roman DD, Sperduto PW (1993) Neuropsychological effects of cranial radiation: current knowledge and future directions. Int J Radiat Oncol Biol Phys 30:983–98

Shaffer R, Nichol AM, Vollans E, Fong M, Nakano S, Moiseenko V, Schmuland M, Ma R, McKenzie M, Otto K (2010) A comparison of volumetric modulated arc therapy and conventional intensity-modulated radiotherapy for frontal and temporal high-grade gliomas. Int J Radiat Oncol Biol Phys 76:1177–84

Stupp R, Hegi ME, Mason WP (2000) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:69–76

Tofilon PJ, Fike JR (2000) The radio response of the central nervous system: adynamic process. Radiat Res 153(4):357–370

Vigliani MC, Duyckaerts C, Delattre JY. Radiation-induced cognitive dysfunction in adults: Handbook of clinical neurology. Edited by: Vincken PJ, Bruyn GW. North Holland, Amsterdam, pp 371–388,1997.